HR Executive, Total Reward Consultant, Job Evaluation Expert with a proven record of designing and delivering effective solutions that support the business strategy and inspire, engage and motivate employees to higher levels of performance throughout a complex multinational organization. A strong communicator with commercial and business acumen, established project and change management skills. Experienced in working with Executives.

With over 18 years in-house and consulting experience in HR and reward, specialisms include: total reward strategy, governance and communication; supporting the Remuneration Committee; executive remuneration; job matching, job architecture and job evaluation; base pay management (salary reviews, budgeting, market pricings, salary structures); short- and long-term incentive design and management; employee benefits; performance management; HRIS; employee recognition; employee well-being; flexible working; project & change management; expert speaker at conferences.
Specialties: HR Strategy, HRM, Compensation & Benefits, Total Reward Consulting, Organizational Development Consulting, Hay Job grading, eIPE & WIN(Mercer), Towers Watsons; Job analysis & description, Job Evaluation, Selection & Recruitment, BDM, sales& marketing, Employer Branding(Universum), Talent Management, Coaching.

Our Vision: “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.